YOLFTbeta
Abivax SA

Abivax SA

ABVX · PA · Healthcare / Biotechnology

79.10EUR-3.40 (-4.12%)

Price History

Full chart

Market Stats

Previous Close82.50
Open81.25
Day Range78.70 – 82.25
52-Week Range60.45 – 139.00
Volume113.83K
Market Cap7.29B
P/E (TTM)0.00
Forward P/E1.00
EPS-5.33
Dividend Yield0.00%
Beta-0.25
50-Day Avg99.07
200-Day Avg101.82

About

ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Marc M. P. de Garidel M.B.A.
  • Employees98
  • Headquarters7-11 Boulevard Haussmann, Paris, France, 75009, France
  • Websitehttps://www.abivax.com

Leadership

  • Mr. Marc M. P. de Garidel M.B.A.CEO & Director · b. 1958
  • Mr. Didier BlondelEVP, CFO & Board Secretary · b. 1964
  • Dr. David Zhang Ph.D.Chief Strategy Officer · b. 1968
  • Dr. Keith M. Fournier Ph.D.Senior Vice President of Global Regulatory Affairs
  • Mr. Michael Nesrallah M.B.A.Chief Commercial Officer
  • Dr. Maurus de la Rosa Ph.D.Senior Vice President of Research
  • Mr. Ivan Nunez-PachecoGlobal Head of Patient Services
  • Ms. Heather DeanGlobal Head of Sales, Accounts & Commercial Operations
  • Mr. Jeffrey N. HaasGlobal Head of Market Access & Pricing

Financials

Income Statement

Currency: EUR2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue74.87K67.13K228.00K151.00K356.00K815.00K-7.00K14.00K37.00K4.58M4.62M10.79M0
Growth (%)--10.33%+239.62%-33.77%+135.76%+128.93%-100.86%+300.00%+164.29%+12286.49%+0.83%+133.54%-100.00%
Cost of Revenue160.99K286.50K14.75M14.64M10.47M15.38M80.00K66.00K156.00K71.00K707.00K1.10M1.07M
Gross Profit-86.12K-219.36K-14.52M-14.49M-10.12M-14.56M-87.00K-52.00K-119.00K4.51M4.49M10.79M-1.07M
Gross Margin-115.02%-326.75%-6370.18%-9598.68%-2841.57%-1786.63%1242.86%-371.43%-321.62%98.45%97.23%100.00%-
Operating Expense7.31M4.83M3.73M3.74M4.03M4.55M33.19M39.54M52.07M69.35M131.87M196.22M249.55M
Operating Income-7.40M-5.05M-18.25M-18.24M-14.15M-19.11M-33.27M-39.59M-52.19M-64.84M-127.38M-185.43M-250.63M
Operating Margin-9879.79%-7528.23%-8006.58%-12076.82%-3974.72%-2344.66%475357.14%-282821.43%-141045.95%-1414.71%-2756.46%-1718.24%-
EBITDA-7.37M-5.00M-18.12M-17.73M-14.06M-19.23M-33.22M-37.74M-42.20M-53.31M-133.21M-167.68M-249.55M
EBITDA Margin-9849.55%-7455.24%-7946.93%-11742.38%-3948.60%-2359.14%474500.00%-269585.71%-114040.54%-1163.32%-2882.64%-1553.76%-
Net Income-5.89M-5.08M-15.96M-14.31M-11.22M-15.82M-30.63M-37.55M-42.45M-60.74M-147.74M-176.24M-336.10M
Net Income Margin-7871.50%-7566.96%-6997.81%-9475.50%-3152.25%-1941.47%437628.57%-268221.43%-114735.14%-1325.33%-3197.14%-1633.08%-
R&D-3.76M15.27M15.46M10.85M15.87M29.01M34.53M47.20M48.73M103.18M146.53M177.76M
R&D as % of Total Revenue-5606.70%6696.05%10237.75%3046.63%1946.99%-414385.71%246614.29%127572.97%1063.17%2232.76%1357.78%-
Interest Expense168.93K110.76K168.00K30.00K39.00K539.00K1.64M2.32M3.56M7.02M13.83M14.11M28.51M
Interest Expense % of Total Revenue225.63%164.98%73.68%19.87%10.96%66.13%-23442.86%16557.14%9616.22%153.22%299.20%130.75%-

Balance Sheet

Currency: EUR2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets38.46M37.97M76.27M60.60M53.81M54.05M51.73M71.30M110.36M73.35M327.06M205.23M584.34M
Total Liabilities4.44M4.03M4.53M3.88M5.63M19.39M39.95M66.63M81.59M71.47M131.05M164.64M129.14M
Total Equity34.02M33.94M71.74M56.72M48.18M34.65M11.78M4.67M28.77M7.19M196.01M40.58M455.20M
Cash2.91M1.22M119.00K7.94M1.88M8.00M9.77M29.30M60.70M26.94M251.94M144.22M516.68M
Total Debt2.32M2.09M435.00K316.00K262.00K11.96M24.10M39.52M63.76M39.16M55.46M97.36M32.09M
Net Debt-587.71K868.96K3.29M-5.41M-1.62M2.90M10.98M4.69M-7.25M19.78M-196.48M-46.86M-484.59M

Cash Flow

Currency: EUR2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-3.31M-3.31M-14.90M-15.61M-8.45M-14.60M-27.47M-29.82M-45.66M-65.58M-97.13M-154.07M-162.09M
Investing Cash Flow-43.00K-43.00K-1.02M-94.00K-105.00K-254.00K-370.00K-575.00K-1.46M-3.73M-8.10M15.76M-13.72M
Financing Cash Flow5.94M5.94M52.13M-438.00K2.60M10.83M24.61M49.93M82.68M32.21M335.29M28.21M553.80M
Capital Expenditure43.00K43.19K1.02M721.00K979.00K763.00K941.00K898.00K1.64M3.97M265.00K643.00K142.00K
Free Cash Flow--3.35M-15.93M-16.33M-9.43M-15.37M-28.41M-30.72M-47.30M-69.55M-97.39M-154.72M-162.23M
Dividends Paid--------00000
FCF to OCF-101.31%106.88%104.62%111.59%105.22%103.43%103.01%103.60%106.05%100.27%100.42%100.09%
Dividend Paid to FCF--------0.00%0.00%0.00%0.00%0.00%

Earnings

Report DateApr 28, 2016Sep 21, 2016Mar 15, 2017May 12, 2017Sep 20, 2017Mar 16, 2018May 30, 2018Sep 28, 2018Nov 28, 2018Mar 14, 2019May 29, 2019Sep 19, 2019Nov 27, 2019Mar 16, 2020Jun 3, 2020Sep 29, 2020Dec 2, 2020Mar 31, 2021Jun 2, 2021Sep 23, 2021Dec 1, 2021Mar 16, 2022Jun 1, 2022Sep 30, 2022Nov 30, 2022Mar 16, 2023Apr 19, 2023Sep 21, 2023Nov 29, 2023Apr 2, 2024Sep 9, 2024Nov 7, 2024Mar 24, 2025Jun 2, 2025Sep 8, 2025Dec 15, 2025Mar 23, 2026May 22, 2026Sep 21, 2026Mar 22, 2027
EPS Estimate0.000.000.000.00-0.860.000.00-0.990.00-0.920.000.000.00-1.470.00-0.990.000.000.000.000.000.000.00-0.00-1.76-1.76-0.66-0.59-0.78-0.65-0.65-0.68-0.66-0.70-0.63-0.98-0.85-0.61-
EPS Actual-0.91-0.86-0.63-0.63-0.57-0.570.00-0.720.00-1.600.00-1.380.00-1.170.00-0.550.00-1.820.00-1.130.00-1.700.00-1.770.000.00-2.39-0.66-0.59-0.79-0.94-0.68-0.73-0.83-0.76-2.10-2.66-0.61-1.47-
Surprise----33.72%--27.27%--73.91%---20.41%-44.44%---------100.00%-35.80%-0.39%0.17%-0.64%-45.08%-5.32%-7.85%-26.51%-9.01%-233.71%-171.43%28.24%-140.98%-
Timing-Pre-marketAfter-hours------------After-hours-------After-hours-After-hours-After-hours-----Pre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hours

Key Statistics & Ratios

Market Cap7.29B
Enterprise Value7.13B
Trailing P/E0.00
Forward P/E1.00
Price / Sales1561.09
Price / Book20.58
EPS-5.33
Book Value4.59
Revenue (TTM)4.67M
Gross Profit (TTM)4.67M
EBITDA-291.55M
Profit Margin0.00%
Operating Margin-8617.93%
Return on Equity-252.35%
Return on Assets-62.88%
Shares Outstanding87.27M
Shares Float69.03M
Beta-0.25
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%